Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trisenox in unresectable liver cancer
NCT00128596Phase 2Completed
- Sponsor
- University of Pittsburgh
- Start
- Jun 2004
- Primary completion
- Dec 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide in hepatocellular carcinoma (HCC), sponsored by University of Pittsburgh. Started Jun 2004; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00128596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00128596.